Advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Chiara Vona — Fri, 01 Dec 2023 08:40:35 +0000

Mike Davis, Head of Global Epilepsy

Chiara Vona Fri 01/12/2023 - 09:40

I’ve been lucky to work for ��ֳ� in the field of epilepsy for more than two decades, and over that period we have established ourselves as leaders in developing innovative medicines and transforming outcomes for people living with epilepsy, and their families. We do not take this responsibility lightly, recognising the importance of meeting real-world needs and ensuring our work is as valuable to as much of the epilepsy community as possible. We are constantly asking questions of ourselves, holding each other to account on behalf of all the lives that we touch.

At this year’s American Epilepsy Society (AES) Annual Meeting in Orlando, USA, the research we are presenting is reflective of that ongoing commitment. We are showcasing 29 abstracts, including 4 late breakers, covering early research, clinical, health economic, and demographic studies in epilepsy.

It’s a truly broad data set, providing new insights in areas such as Dravet syndrome, Lennox-Gastaut syndrome, epilepsy and pregnancy, focal-onset seizures, SUDEP, and for individuals who experience prolonged seizures, all with a focus on elevating epilepsy care today. We also touch on potential treatments of tomorrow, presenting some of our early discovery research work in our ongoing pursuit of treatments that could one day alleviate the underlying causes of epilepsies. We also explore factors contributing to health disparities amongst those living with epilepsy, and what can be done to bring about change.

This year, we are also excited to be partnering with the AES as the exclusive sponsor of components of their Diversity, Equity, and Inclusion (DE&I) initiatives at the AES 2023 Annual Meeting. This collaboration signifies our shared values and commitment to fostering an environment of inclusivity, diversity, equity, and excellence. Through this collaboration, ��ֳ� supports AES's aim to provide essential career support for both current and emerging epilepsy scientists and clinicians who belong to historically underrepresented groups and underserved populations. By doing so, we seek to bridge gaps and promote equitable opportunities within the epilepsy community.

We are proud of the innovation and impact we have been able to deliver over the past three decades, and we will continue to reimagine how we care for patients, and to progress science that can impact real, unmet needs. If you’re attending the AES Annual Meeting this week, please do come and say hello at the ��ֳ� booth, to carry on the conversation on how we can do more for patients.

solutions

895 Likes

��ֳ� at AES 2022: Why 30 Years in Epilepsy are just the beginning

Vanco Vlastimil (��ֳ� S.A.) — Thu, 01 Dec 2022 08:00:00 +0000

��ֳ� at AES 2022: Why 30 Years in Epilepsy are just the beginning

Konrad Werhahn, Global Epilepsy Strategy

Vanco Vlastimi… Thu 01/12/2022 - 09:00

For millennia, doctors and scientists around the world have been searching for better treatments for epilepsy. At ��ֳ�, we’ve been working in epilepsy care for more than 30 years. Yet in some ways, the evolution of epilepsy care is just getting started.

Modern science is giving us more information about this disease than we’ve ever had before. That’s why opportunities to gather and connect with industry leaders and peers within the epilepsy space – like the 2022 Meeting of the American Epilepsy Society (AES), taking place over the next several days – are so important. These events play a key role in furthering understanding and awareness of the complexities of epilepsy. And with more than three decades at the forefront of epilepsy care, ��ֳ� is continuing to advance the science and understanding of epilepsies, particularly rare epilepsies, and those with high unmet needs.

The science behind treating epilepsy is moving in exciting new directions, and the scientific discussions and debate that happen at AES help inform our research agenda. We are working towards a future where we hope to impact the underlying causes of certain epilepsies and change the course of disease. Powered by a team of dedicated scientists and experts in epilepsy care, it is our long-term goal that one day, we can develop solutions that move from symptomatic relief to those that could address the underlying causes of certain epilepsies.

But we can’t do this alone. As we test and learn, we network with healthcare professionals, academic centers, the research community, and patients, so we can all share our expertise and experience in epilepsy and bring about meaningful change in the lives of those living with epilepsy. We are acutely aware of the ongoing unmet medical need for people living with this condition, and ��ֳ� is committed to playing our part to help.

��ֳ� is proud to have 21 abstracts accepted at AES 2022, reinforcing our decades-long commitment to transforming epilepsy care. To create a new future of epilepsy treatment and care, it’s going to take a village. I’m excited to brainstorm with industry peers on challenging the status quo, discovering new possibilities, and advocating for this resilient community.

You can follow along with ��ֳ� at #AES2022 by checking out our social accounts (Facebook, Twitter, LinkedIn) for more updates and information.

about ucb

AES American Epilepsy Society epilepsy

415 Likes

AES

Advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Leave a Comment

��ֳ� at AES 2022: Why 30 Years in Epilepsy are just the beginning

Leave a Comment

AES

Advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Leave a Comment

������ֳ� at AES 2022: Why 30 Years in Epilepsy are just the beginning

Leave a Comment

��ֳ� at AES 2022: Why 30 Years in Epilepsy are just the beginning